Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Aug 28;105(5):492-9.
doi: 10.1161/CIRCRESAHA.109.198572. Epub 2009 Aug 6.

Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity

Affiliations

Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity

Dorothy A Hanck et al. Circ Res. .

Abstract

Rationale: Lidocaine and other antiarrhythmic drugs bind in the inner pore of voltage-gated Na channels and affect gating use-dependently. A phenylalanine in domain IV, S6 (Phe1759 in Na(V)1.5), modeled to face the inner pore just below the selectivity filter, is critical in use-dependent drug block.

Objective: Measurement of gating currents and concentration-dependent availability curves to determine the role of Phe1759 in coupling of drug binding to the gating changes.

Methods and results: The measurements showed that replacement of Phe1759 with a nonaromatic residue permits clear separation of action of lidocaine and benzocaine into 2 components that can be related to channel conformations. One component represents the drug acting as a voltage-independent, low-affinity blocker of closed channels (designated as lipophilic block), and the second represents high-affinity, voltage-dependent block of open/inactivated channels linked to stabilization of the S4s in domains III and IV (designated as voltage-sensor inhibition) by Phe1759. A homology model for how lidocaine and benzocaine bind in the closed and open/inactivated channel conformation is proposed.

Conclusions: These 2 components, lipophilic block and voltage-sensor inhibition, can explain the differences in estimates between tonic and open-state/inactivated-state affinities, and they identify how differences in affinity for the 2 binding conformations can control use-dependence, the hallmark of successful antiarrhythmic drugs.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Gating charge-voltage (Q–V) relationships for WT (A) and F1759K (B) channels before and after exposure to 10 mM lidocaine. Insets show Ig for representative cells in step depolarizations to 0 mV in the absence and presence of 10 mM lidocaine. The Qmax from the Boltzmann fits to the individual cell's Q–V relationships in control solution (□) was used to normalize the Qmax in lidocaine (▲) and after wash (○). The protocols were done from a holding potential (Vhp) of −150mV. (A) For WT (n=2 cells) the Qmax after lidocaine was 0.67 ± 0.02 of control, V½ shifted from −67 ± 4 mV to −80 ± 5 mV, and the slope factor flattened (−12 ± 3 mV to −20 ± 3 mV). All changes were significant at p<0.05. The inset shows that Ig was decreased in drug. (B) For F1759K channels (n = 4 cells) in lidocaine Qmax was 0.99 ± 0.01 of control, and the slope factor was unchanged after lidocaine (13 ± 1 mV in both groups). V ½ was significantly shifted from −72 ± 2 mV to −80 ± 1 mV. In the inset, both Ig traces appear superimposed.
Figure 2
Figure 2
Steady-state voltage-dependent Na channel availability protocol (A, bottom) showing data for a representative cell expressing F1759K channels in control (left) and after exposure to 1 mM lidocaine. Summary data for cells expressing WT (B) and F1759K (C) channels exposed to lidocaine. Means ± SEM in control solution are shown as open symbols, and in the presence of various concentrations of lidocaine as filled symbols. (B) Data for 0.5 mM (●, n=5) and 1 mM (♦, n=3) lidocaine are shown. Vhp was −150 mV. Mean ± SEM for parameters to fits with individual datasets: half-point −93 ± 1 mV (control), −122 ± 2.8 mV (0.5 mM), and −126 ± 4.3 mV (1 mM); slope factor: 5.3 ± 0.3 mV (control), 6.0 ±0.8 mV (0.5 mM), and 6.2 ± 1.2 mV (1 mM). Inset shows summary of shifts in V½ of availability for cells exposed to four concentrations of lidocaine including cells exposed to 5 µM (n=7) and 50 µM (n=9), concentrations at which little reduction in Imax was evident (data not shown). (C) Data for F1759K exposed to 1 mM (♦, n=8), 3 mM (■ , n=4) and 10 mM (▲, n=3) lidocaine. Means ± SEM of parameters for fits to individual datasets were for half-point: −91 ± 1 mV (control), −104 ± 1 mV (1 mM), −103 ± 2 mV (3 mM), and −102 ± 1 mV (10 mM), and for slope factors: 6.2 ± 0.3 mV (control), 6.4 ± 0.6 mV (1 mM), 7.3 ± 0.8 mV (3 mM), and 9.3 ± 1.7 mV (10 mM). Inset shows concentration response relationship of tonic block, estimated from the fitted asymptotes of the availability relationships. ED50's were 0.78 mM ± 0.2 mM for WT, and 2.2 mM ± 0.2 mM for F7159K.
Figure 3
Figure 3
Q–V relationships for WT (A) and F1759K (B) channels exposed to 2 mM benzocaine. The Qmax from the Boltzmann fits to the individual cell's Q–V relationships in control solution (□) was used to normalize the Qmax in 2 mM benzocaine (◄) and after wash (○). Vhp was −150mV. (A) For WT (n=3) Qmax in benzocaine was 0.85 ± 0.03 of control, V½ shifted from −62 ± 5 mV to −76 ± 4 mV, and s, the slope factor, flattened from −12 ± 2 mV to −17 ± 2 mV. All three changes were significant. Under similar experimental conditions used for these gating current recordings, peak INa was decreased by 58% ± 1% (n=3, data not shown). (B) For F1759K channels (n = 4 cells) Qmax in benzocaine was unchanged at 1.0 ± 0.01and the slope factor was unchanged (−10.9 ± 0.4 mV in control and −11.4 ± 0.2 mV in benzocaine). The shift in V ½ was significant from −69 ± 2 mV to −76 ± 2 mV.
Figure 4
Figure 4
Steady-state voltage-dependent Na channel availability of WT (A) and F1759K (B) channels exposed to benzocaine. Protocol as described in Methods. (A) WT in control (□), 0.3 mM (►, n=3), 0.5 mM (●, n=7), 1 mM (♦, n=6), and 2 mM (◄, n=4) benzocaine. Vhp was −135 or −150 mV. The dashed lines represent the solid lines fitted to mean data but scaled to a value of one, and adjusted for the background shift in kinetics based upon the difference in time between recordings. Means ± SEM of parameters to fits to individual datasets are for half-point: −88 ± 1 mV (control), −101 ± 1 mV (0.3 mM), - +106 ± 2 mV (0.5 mM), 117 ± 2 mV (1 mM), and −122 ± 4 mV (2 mM) and slope factor: 6.7 ± 0.2 mV (control), 6.6 ± 0.5 mV (0.3 mM), 9.0 ± 0.8 mV (0.5 mM), 8.8 ± 0.3 mV (1 mM), and 8.5 ± 0.5 mV (2 mM). Inset shows the concentration response for tonic block calculated from the means ± SEM of the Imax from the fits of the individual datasets by a Boltzmann (see Methods) normalized to the Imax in control. Single-site concentration-response fit (see Methods) estimated the ED50 to be 0.32 ± 0.02 mM. (B) F1759K channels in control (□), 1 mM (♦, n=5) and 2 mM (◄, n=4) benzocaine. The dashed lines represent data scaled to a value of one and adjusted as described above. V1/2 shifted −8.3 ± 0.7 mV (1 mM) and −9.7 ± 1.1 mV (2 mM). Means ± SEM of parameters from fits to individual datasets were for half-point: −91 ± 1 mV (control), −100 ± 2 mV (1 mM), and −99 ± 2 mV (2 mM), and for slope factor: 6.2 ± 0.2 mV (control), 5.4 ± 0.3 mV (1 mM), and 7.1 ± 0.3 mV (2 mM). Inset shows the concentration-response relationship calculated from the means ± SEM of the Imax from the fits of the individual datasets by a Boltzmann (see Methods) normalized to the Imax in control. Solid line shows the single-site concentration-response relationship; ED50 was 0.66 ± 0.10 mM.
Figure 5
Figure 5
Proposed location for lidocaine (A,B) and benzocaine (C,D) in the closed (A,C) and open/inactivated Na channel (B,D). Lidocaine and benzocaine are shown as space-filled docking in the interface of IIIS6–IVS6 (green ribbons). Green color represents C atoms, blue represents N atoms, and red represents O atoms. Amino acid residues making contacts with drugs are shown by blue (IIIS6) and red (IVS6) colors. The optimized structures of the complexes with the inner pore were calculated with the Discover module of Insight II. It should be noted that because of the differences in sizes between residues in NaV1.5 when compared to those in KcSA, construction of the homology model in Na channel with its bulky residues required additional optimization of the structure at the S6 crossing to avoid nonbonded repulsion between side chains. The tertiary amine of lidocaine and the primary amine of benzocaine are predicted to be oriented similarly in the open/inactivated channel where the drugs adopt a vertical orientation. The aromatic ring of benzocaine fits into the interface between DIIIS6 and DIVS6. (E, F) Lidocaine and benzocaine are shown aligned as they are oriented in the closed channel and in the open/inactivated channel. In the closed channel both are oriented more horizontally (E) with their aromatic rings aligned with Phe1759.

Similar articles

Cited by

References

    1. Starmer CF, Hollett MD. Mechanisms of apparent affinity variation of guarded receptors. J Theor Biol. 1985;115:337–349. - PubMed
    1. Hille B. Local anesthetics: Hydrophilic and hydrophobic pathways for the drug-receptor reaction. J. Gen. Physiol. 1977;69:497–515. - PMC - PubMed
    1. Li HL, Galue A, Meadows L, Ragsdale DS. A molecular basis for the different local anesthetic affinities of resting versus open and inactivated states of the sodium channel. Mol Pharmacol. 1999;55:134–141. - PubMed
    1. Liu H, Atkins J, Kass RS. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol. 2003;121:199–214. - PMC - PubMed
    1. McNulty MM, Edgerton GB, Shah RD, Hanck DA, Fozzard HA, Lipkind GM. Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels. J Physiol. 2007;581:741–755. - PMC - PubMed

Publication types

MeSH terms